NETs: Capecitabine plus temozolomide gives longer PFS than temozolomide alone
Dr Pamela Kunz speaks to ecancer about a randomised study, known as E2211, of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumours.
She continues by outlining the methodology of the study.
Dr Kunz then summarises the key findings which showed the longest PFS and highest RR reported for advanced pancreatic neuroendocrine tumours
Watch video NETs: Capecitabine plus temozolomide gives longer PFS than temozolomide alone online without registration, duration hours minute second in high quality. This video was added by user ecancer 15 June 2022, don't forget to share it with your friends and acquaintances, it has been viewed on our site 68 once and liked it people.